ABSTRACT Calcimycin, N-demethyl calcimycin, and cezomycin are polyether divalent cation ionophore secondary metabolites produced by Streptomyces chartreusis. A thorough understanding of the organization of their encoding genes, biosynthetic pathway(s), and cation specificities is vitally important for their efficient future production and therapeutic use. So far, this has been lacking, as well as information concerning any biosynthetic relationships that may exist between calcimycin and cezomycin. In this study, we observed that when a Cal Ϫ (calB1 mutant) derivative of a calcimycin-producing strain of S. chartreusis (NRRL 3882) was grown on cezomycin, calcimycin production was restored. This suggested that calcimycin synthesis may have resulted from postsynthetic modification of cezomycin rather than from a de novo process through a novel and independent biosynthetic mechanism. Systematic screening of a number of Cal Ϫ S. chartreusis mutants lacking the ability to convert cezomycin to calcimycin allowed the identification of a gene, provisionally named calC, which was involved in the conversion step. Molecular cloning and heterologous expression of the CalC protein along with its purification to homogeneity and negative-staining electron microscopy allowed the determination of its apparent molecular weight, oligomeric forms in solution, and activity. These experiments allowed us to confirm that the protein possessed ATP pyrophosphatase activity and was capable of ligating coenzyme A (CoA) with cezomycin but not 3-hydroxyanthranilic acid. The CalC protein's apparent K m and k cat for cezomycin were observed to be 190 M and 3.98 min Ϫ1 , respectively, and it possessed the oligomeric form in solution. Our results unequivocally show that cezomycin is postsynthetically modified to calcimycin by the CalC protein through its activation of cezomycin to a CoA ester form.
observed that its production of calcimycin was restored ( Fig. 2A) . As a double confirmation of the identity of the product, calcimycin, it was recovered by highpressure liquid chromatography (HPLC) from the reaction mixtures and subjected to HPLC and high-resolution mass spectrometry. This unequivocally confirmed its identity (Fig. 2B) .
Identification and confirmation of the roles of the genes involved in cezomycin modification. Elucidation of the biological significance of the calC-, calD-, calU3-, and calF-encoded proteins in calcimycin biosynthesis was facilitated by (i) creation of related defective (calcimycin-nonproducing) mutants (Table 1) and (ii) their complementation with plasmids bearing the corresponding active gene under the control of a constitutive ermE promoter (Table 1 ). In the calC, calD, calU3, and calF mutant strains, the apr resistance gene had replaced most of the corresponding protein-coding sequence. Results from these experiments are shown in Fig. 3 ; see also Fig. S2 in the supplemental material. These data show that the calC, calU3, and calF genes are clearly involved in the modification of cezomycin ( Fig. 3 and S2) , as restoration/complementation of lost gene function restored product formation. The results for calD are less clear in that context.
Biochemical characteristics of CalC protein.
From its gene sequence, it is possible to deduce that CalC is an adenylate-forming enzyme that might activate the carboxylic acids for the subsequent biochemical biosynthesis (16) and that it is composed of 521 4B ). This is likely to indicate that CalC protein adopts an oligomeric form in solution and is somewhat confirmed from the results of electron microscopy on CalC-His protein purified to homogeneity by Ni-affinity column and cation exchange and size exclusion chromatography (Fig. 4A , B, and C). In Fig. 4D (a typical image), particles with regular shapes can be observed. The mutant CalC protein lacking the entire ATP-binding region was subjected to a similar analysis and was also observed to display an oligomeric form similar to that of the functional CalC protein (see Fig. S3 in the supplemental material).
CalC is an ATP-dependent cezomycin-CoA ligase. Pyrophosphate assay and product analysis with Q-TOF indicated that CalC possessed ATP hydrolysis activity. In these experiments, a CalC mutant in which the entire putative ATP-binding region was deleted was used as a negative control, and the results showed that AMP is the ATP hydrolysis product of the reaction catalyzed by CalC and that CalC possesses ATP pyrophosphatase activity rather than ATPase activity ( Fig. 5A and B) . In the presence of ATP, CoA-SH, MgCl 2 , and cezomycin, it was the purified CalC-His protein, but not the heat-inactivated or ATP-binding mutant CalC protein, that catalyzed the production of cezomycin-CoA (Fig. 5C ). Product confirmation was by reversephase HPLC/MS and its molecular mass/charge ratio (m/z), 1244.3515, was determined using high-resolution mass spectrometry and MS fragmentation peaks. This coincided well with those produced by a cezomycin-CoA standard used for comparison ( Fig. 5D ; see also Fig. S4 in the supplemental material). Compound 3, N-demethyl-calcimycin, calcimycin, the benzoxazole moiety precursor-3HA, and benzoate were not observed to be acted upon by the CalC protein (see Table S2 and Fig. S5 and S6 in the supplemental material). It is possible to suggest that the CalC protein is responsible for activating cezomycin to its CoA thioester adduct.
The activity of CalC was observed to be dependent upon the presence of either magnesium or manganese ions but not of calcium or iron ions (see Table S3 (19) (20) (21) (22) (23) . The adenylation domain is thought to be responsible for the enzyme's carboxyl substrate specificity and is responsible for the generation of the substrates corresponding to carboxyl adenylate adduct in the presence of ATP (24) .
These observations confirm and support the hypothesis that we have presented above based upon results from our experiments, i.e., that CalC functions as a CoA ligase in the synthesis of calcimycin from cezomycin in the presence of ATP.
(ii) CalD protein.
Our previous in silico analysis of CalD protein indicated that it resembled NAD(P)H-dependent oxidoreductases/dehydrogenases (16), and results from experiments reported here have shown that its physical disruption resulted in a slight decrease, but not abolishment, of the production of calcimycin. Consequently, the exact function of the gene in calcimycin biosynthesis is, unfortunately, still unclear.
calU3 and calF genes. From our previous in silico analysis of the calU3 and calF (16) genes, we know that they share significant DNA sequence identities with the creE (68%) and creD (60%) genes of Streptomyces cremeus (25) , respectively. The CreE and CreD proteins are known to be responsible for the formation of nitrous acid, which has a role in diazo group generation in this organism's biosynthesis of the ortho-diazoquinone containing secondary metabolite cremeomycin (25) . In this work, we report that the disruption of calU3 and calF genes diminished the production of calcimycin significantly ( Fig. S2 ) but that the addition of inorganic nitrite (NaNO 2 ) to the culture medium of such mutants restored their production of calcimycin (see Fig. S10 in the supplemental material). Further, our in vitro study revealed the involvement of CalU3 and CalF in generating nitrous acid (see Fig. S11 in the supplemental material).
Put together, these observations suggest that the calU3 and calF genes are involved in specifying proteins involved in the biosynthesis of calcimycin from cezomycin by way of the formation of nitrous acid.
DISCUSSION
Our results reported here support the view that calcimycin is derived from cezomycin in a reaction catalyzed by the CalC protein that is energy dependent, transforming ATP to AMP; CalC functions as a CoA ligase and catalyzes the conversion of cezomycin to cezomycin-CoA. Our data might also suggest that cezomycin might then be further modified to calcimycin (Fig. 6) . It was suspected that in the calcimycin production there might be a hydroxylation step at the C-3 position of cezomycin and the CalD protein might be responsible for this step (16) . The CalD protein was implicated previously as an orthologue to known NAD(P)H-dependent oxidoreductases (16) , and yet the deletion of the gene did not obviously affect calcimycin/cezomycin metabolism. Therefore, whether there is such a hydroxylation step of cezomycin involving CalD remains unclear. Since our evidence revealed that supplement of inorganic nitrite (NaNO 2 ) to calU3 and calF mutant strains restored their calcimycin production and the CalU3 and CalF proteins can generate nitrous acid (Fig. S2 , S10, and S11), it is therefore reasonable to suggest that the two genes are involved in providing the nitrogen source for the amination of cezomycin at its C-3 position (16). The biosynthetic mechanism suggested above, i.e., the modification of a closely related calcimycin precursor (which possesses no or significantly reduced biological activity), might allow a significant protective advantage for the producing host bacteria. In that context, although ionophore-mediated transport of specific ions across cell membranes has been well studied (14, 26, 27) , little is known about the physiological effects of the molecules on their bacterial producing organisms (28) . The results of our work allow us propose the possibility that calcimycin (polyether divalent cation ionophore)-producing organisms can avoid the likely negative consequences of the intracellular presence of such molecules (possible cation depletion) by "stockpiling" a close precursor, cezomycin, that possesses a binding affinity for cations 10 times less than that of calcimycin (1) . In times of need (metabolic stress or environmental competition from other organisms [28] ), such a precursor could then be rapidly converted to its "active form," in this case, calcimycin. In this context, the K m of CalC for cezomycin is around 190 M, and this concentration may be of physiological relevance.
MATERIALS AND METHODS
Bacterial strains, genomic DNA, plasmids, and culture conditions. Bacterial strains and plasmids used in the study are listed in Table 1 . Escherichia coli plasmid isolation, gene cloning, and other routine molecular biological procedures were performed as described by Sambrook and Russell (29) . S. chartreusis NRRL 3882 genomic DNA was isolated according to the protocol of Kieser et al. (30) .
Escherichia coli strains were maintained and grown in or on liquid or solid Luria broth (LB). Small-scale growth of S. chartreusis NRRL 3882 and its derivative strains was by culture in TSBY liquid medium, containing 3% tryptone soy broth, 10.3% sucrose, and 0.5% yeast extract (for extraction of chromosomal DNA), or on SFM agar, containing 2% mannitol, 2% soybean powder, and 2% agar (pH 7.2) (for sporulation and conjugation). Liquid fermentation of S. chartreusis NRRL 3882 and its derivative mutant strains was performed in SFM medium without agar. Media were supplemented when necessary with 50 g liter Ϫ1 apramycin.
Inactivation and complementation of calC, calD, calU3, and calF genes. The calC, calD, calU3, and calF genes in S. chartreusis strain NRRL 3882 were replaced by the apr resistance gene, using Redirect Technology (31) as described in the product literature. Briefly, the apr resistance gene from pIJ773 (31) (Table 1) was amplified using KOD-plus DNA polymerase (Toyobo Biotech Co. Ltd.) and calC, calD, calU3, and calF gene-specific primers (Table 3 ). The resulting amplification products were introduced into E. coli BW25113/pIJ790 harboring p14F11 or p6F5 (16) to generate plasmids pJTU3763 (ΔcalC), 3764 (ΔcalD), pJTU3770 (ΔcalU3), and pJTU3771 (ΔcalF). These plasmids were then introduced into S. chartreusis NRRL 3882 by conjugation with E. coli ET12567/pUZ8002, and double crossover Apr r mutants were isolated by selection on SFM medium containing apramycin. The identity of the mutants was confirmed by PCR and double-stranded sequencing of amplification products. Gene complementations of S. chartreusis ⌬cal mutant strains were achieved by introducing plasmids possessing full-length complementary DNA into the gene deletion strains. Briefly, calC, calD, calU3, or calF genes were PCR amplified from the purified genomic DNA of S. chartreusis NRRL 3882 strain by using gene-specific primers (Table 3) . After size and sequence confirmation, PCR products were ligated into vector plasmid pJTU2170 (32) to generate complementation plasmids, namely, pJTU3777 (calC), pJTU3778 (calD), pJTU3780 (calU3), and pJTU3784 (calF), and stabilized in E. coli ET12567. These plasmids were then introduced into S. chartreusis ⌬cal strains GLX4 (ΔcalC), GLX6 (ΔcalD), GLX11 (ΔcalU3), or GLX18 (ΔcalF) ( Table 1 ) via conjugation with the appropriate E. coli ET12567 complementation-bearing strain to produce GLX5 (ΔcalC/calC), GLX7 (ΔcalD/calD), GLX12 (ΔcalU3/calU3), or GLX19 (ΔcalF/calF). Gene expression in the complementation plasmids was constitutive and under the control of an ermE promoter (30) . Complemented conjugation products were selected by virtue of their kanamycin resistance (growth on LB supplemented with 50 g liter Ϫ1 kanamycin), and their identities were confirmed by PCR amplification and sequencing of the full-length gene.
LC/MS analysis of molecules of interest from fermentation culture. For liquid chromatographymass spectrometry (LC/MS) analysis, S. chartreusis NRRL 3882 (wild type) and its derivative ΔcalC, ΔcalD, ΔcalU3, ΔcalB1 (17) , and ΔcalF mutant strains were precultured in 10 ml of TSBY medium in a 50-ml conical flask at 30°C with gentle shaking at 220 rpm for 48 h, after which 5 ml of the resultant cultures was aseptically removed and inoculated into 500-ml baffled flasks containing 100 ml liquid SFM medium (pH 7.3). Cultivation was continued at 30°C with shaking at 220 rpm for 9 days. For the determination of strain GLX ΔcalB1's ability to convert cezomycin to calcimycin, cezomycin feeding experiments were conducted, in which 0.02 mmol of cezomycin dissolved in 0.5 ml dimethyl sulfoxide (DMSO) was added to the culture 2 days following inoculation of the mutant spores in liquid SFM medium, and the culture was allowed to incubate for a further 7 days. After this time, the 100 ml was centrifuged at 6,000 ϫ g for 30 min to remove cells and cellular debris, and the supernatant was used to assay for calcimycin after extraction with 1.5 volumes of ethyl acetate. Extracted calcimycin was dried under vacuum in a rotary evaporator and then redissolved in 0.5 ml methanol and assayed using an Agilent 1100 series LC/MSD Trap system (Agilent Technologies, Tokyo, Japan) fitted with an Agilent Zorbax SB-C18 (4.6-by 150-mm) column (Agilent Technologies). Sample separation was performed using gradient mixtures of solution A (0.1% formic acid in water) and solution B (0.1% formic acid in methanol), as follows: 75% to 85% of solution B for 8 min, followed by 85% to 95% for 14 min, 95% to 100% for 7 min, and finally 100% of solution B for 6 min at a flow rate of 0.4 ml min Ϫ1 . Eluate was monitored by UV adsorption at a wavelength of 280 nm ( 280 nm ), and a calcimycin standard was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany) for comparison. Eluate producing a peak at 280 nm was collected and subjected to high-resolution mass spectrometry using an Agilent 6530 Series Accurate-Mass quadrupole time of flight (Q-TOF) LC/MS (Agilent Technologies) to reconfirm product identity by M r . Synthesis and purification of cezomycin and cezomycin-CoA. S. chartreusis NRRL 3882 was cultured for 9 days in 15 1-liter conical flasks, each containing 400 ml SFM medium, to make 6 liters at 30°C while gently shaking at 220 rpm, after which cells and cellular debris were removed by centrifugation at 6,000 ϫ g for 30 min in 500-ml polypropylene centrifuge bottles in an Eppendorf 5810 R centrifuge (Eppendorf AG, Hamburg, Germany). The supernatant was then divided into 500-ml volumes, each of which was carefully transferred to a 2-liter separating funnel and thoroughly mixed with 750 ml of dried ethyl acetate. The mixture was allowed to settle for 10 min to permit phase separation, and the upper ethyl acetate layer was collected, placed in a rotary evaporator, and dried in vacuo for 1 h. The dried product (from 6 liters of fermentation broth) was redissolved in 5 ml 90% (vol/vol) aqueous methanol, layered onto a reversed-phase silica gel (AAG 12S50; YMC Co. Ltd.) column, and eluted with aqueous methanol in a gradient from 70% to 100% at a flow rate of 0.5 ml min Ϫ1 . Ten-milliliter fractions were collected from the column, and 20 l from each fraction was analyzed using HPLC/MS as described above. Cezomycin identity in the eluate was confirmed by comparison of HPLC retention time, UV spectrometry, and mass with a cezomycin standard (16) . Fractions, around 20 ml, containing cezomycin were pooled and concentrated in a rotary evaporator under vacuum for 1 h. Typically, approximately 60 mg cezomycin can be obtained from 6 liters liquid culture.
The in vitro synthesis of cezomycin-CoA was conducted using the method of Belshaw et al (33) , and all necessary reagents were purchased from Sigma-Aldrich (Merck KGaA). Briefly, 10 mg cezomycin (0.02 mmol) was mixed with 30 mg coenzyme A (0.03 mmol), 25 mg (0.05 mmol) PyBOP (benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate), and 30 mg potassium carbonate (0.2 mmol) in a 50-ml conical flask, and 5 ml of a 1:1 THF (tetrahydrofuran)-water mixture was added. The solution was gently mixed for 2 h at room temperature, after which the precipitate was removed by centrifugation at 15,000 ϫ g for 10 min. The supernatant containing the cezomycin-CoA adduct was loaded onto a YMC column (AAG 12S50; YMC Co. Ltd.) and eluted with a gradient of 10 mM ammonium acetate in aqueous methanol from 10% to 100% over a 240-ml volume. Five-milliliter fractions were collected, from which 20 l was removed for the assay of cezomycin-CoA by HPLC/MS using an Agilent Zorbax SB-C 18 (4.6-by 150-mm) column at a flow rate of 0.4 ml min Ϫ1 , and solution A (10 mM ammonium bicarbonate, pH 6.7) was gradually replaced by 2 to 30% volumes of solution B (methanol) over a period of 8 to 14 min, 30 to 70% volumes for 14 to 25 min, and then 70 to 100% volumes for 25 to 28 min. The elution was monitored by UV spectroscopy at 254 nm . Fractions containing cezomycin-CoA (around 10 ml) were pooled and concentrated under vacuum in a rotary evaporator. The molecular identity of the cezomycin thioester derivative was confirmed by Q-TOF LC-MS (Agilent 6530 series accurate-mass Q-TOF LC/MS; Agilent Technologies) by an ion peak at m/z of 1,244.34 (see Table S1 and Fig. S1 in the supplemental  material) .
Cloning, expression, and purification of CalC-His protein.
The calC gene was cloned in frame with the poly-histidine codons in the pET28a(ϩ) expression vector (Novagen, Merck KGaA) according to the manufacturer's instructions. Initially, the calC gene was amplified by PCR using purified genomic DNA extracted from S. chartreusis NRRL 3882 and primers 28awhC-F1 and 28awhC-F2 (Table 3) , and after product identity confirmation by agarose gel electrophoresis and bidirectional sequencing it was ligated into pET28a(ϩ), which had been linearized by double digestion with NdeI and XhoI. The ligation product, pJTU3662, was stabilized by introduction into CaCl 2 -treated E. coli DH10B (29) .
Similarly, a calC gene mutant with an altered ATP binding domain was also cloned. Briefly, genespecific primers 28AwhC-F3 and 28AwhC-F4 (Table 3) were used to PCR amplify a target DNA fragment from the cloned calC gene on plasmid pJTU3662. The resulting PCR product contains homologous recombinant arms, which facilitate its cyclization once introduced into host E. coli. Introduction of the PCR fragment into E. coli strain DH10B resulted in the generation of plasmid pJTU3663, which was reisolated, purified, and transformed into E. coli strain BL21(DE3)/plysS (Agilent Technologies) for use in heterologous gene expression.
Production of cloned poly-His-tagged calC and ΔcalC mutant protein was done according to the protocols given by Novagen and was achieved by growth of CalC ϩ and CalC Ϫ E. coli strains in 1 liter of LB medium at 37°C containing 50 g ml Ϫ1 kanamycin and 25 g ml Ϫ1 chloramphenicol with shaking at 250 rpm to an A 600 nm of 0.6. Protein expression was then induced by addition of 1 ml of 0.4 mM isopropyl-D-thiogalactopyranoside (IPTG) solution, and the culture was allowed to incubate for a further 24 h at 16°C. Cells were then harvested by centrifugation and stored frozen at Ϫ80°C for subsequent protein extraction and purification.
Recombinant His-tagged CalC and CalC ATP binding mutant proteins were recovered from 4 g of frozen E. coli cells that were thawed on ice and resuspended in 50 ml of buffer A (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 5% glycerol, 40 mM imidazole, and 1 mM ATP) and lysed by sonication. Cell debris was removed by centrifugation at 20,000 ϫ g for 40 min at 4°C, and the resulting supernatant was loaded onto a nickel-nitrilotriacetic acid (NTA) resin, HisTrap HP 1-ml column (GE Healthcare Life Sciences, Little Chalfont, UK) preequilibrated with buffer A. The column was then washed with 5 bed volumes of buffer C (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 5% glycerol, and 80 mM imidazole) to facilitate His-tagged protein binding, followed by 2.5 bed volumes of elution buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 5% glycerol, and 500 mM imidazole). The total eluate following elution buffer addition (2.5 ml) was collected and loaded onto a Mono S 5/50 GL column (GE Healthcare Life Sciences), preequilibrated with buffer D (50 mM Tris-HCl [pH 7.5], 50 mM NaCl, and 5% glycerol), and eluted at a rate of 1 ml min Ϫ1 by addition of a linear gradient of NaCl at concentration of 50 mM to 1 M. Three-milliliter fractions were collected and monitored for CalC-His protein using SDS-PAGE. Ten microliters of each fraction was loaded onto a 15% polyacrylamide gel along with a size marker (Tiangen, Shanghai, China) for comparison. Samples were electrophoresed at a constant 25 V for 1 h or until the loading dye had reached the bottom of the gel. Fractions identified as containing protein were stored frozen at Ϫ80°C until required.
Determination of the apparent molecular mass of the CalC-His protein. Peak fractions as described above identified as possessing CalC-His protein and its related ATP binding mutant protein were further purified on a Superdex 200 10/300 GL column (GE Heathcare Life Sciences) using an elution solution of 50 mM Tris-HCl (pH 7.5), 300 mM NaCl, and 5% glycerol. The column was first size calibrated using four molecular mass markers (thyroglobulin, 669 kDa; ferritin, 450 kDa; aldolase, 158 kDa; bovine serum albumin [BSA], 67 kDa; obtained from GE Healthcare Life Sciences) (29) and the molecular mass of CalC-His protein was obtained by comparison in terms of its elution point (29) .
Electron microscopy. CalC-His protein and the related ATP binding mutant proteins were imaged on a Tecnai 12 transmission electron microscope (EM; Thermo Fisher Scientific, Waltham, MA, USA) operating at 120 keV and at a magnification of ϫ42,000 with a nominal defocus ranging from Ϫ0.8 to Ϫ0.3 m. Images were acquired using a Gatan Eagle 4k ϫ 4k charge-coupled-device (CCD) camera (Thermo Fisher Scientific), with a final pixel resolution size of 2.71 Å.
CalC and mutant protein activity assays. An EnzChek pyrophosphate assay kit (product number E-6645; Thermo Fisher Scientific) was used to assess the activities of CalC-His and CalC-His mutant protein using the method described in the manufacturer's literature. The activity assay buffer employed in these experiments contained 50 mM Tris-HCl (pH 7.5), 1 mM MgCl 2 , 1 mM ATP, 0.5 mM CoA, and 0.2 mM cezomycin, and the total reaction volume was 100 l. Reactions were initiated by addition of 0.05 mg of purified CalC-His or CalC-His mutant or boiled (denatured) protein (as a negative control) to the reaction mixture. Reactions were performed in triplicate in a quartz cuvette, and the absorbance of the solution at 360 nm was measured continuously at 30°C over a period of 2 h in a PerkinElmer Lambda 650 spectrophotometer (PerkinElmer, Waltham, MA, USA). This allowed the conversion of the substrate, 2-amino-6-mercapto-7-methylpurine ribonucleoside (MESG), to ribose 1-phosphate and 2-amino-6-merc apto-7-methylpurin to be monitored. The reaction rate was calculated by plotting the change in absorbance against time and measuring the slope of the graph.
Triplicate assays were also performed in microcentrifuge tubes at 30°C, in a similar manner but with 0.2 mM each of the following substrates: cezomycin, N-demethyl-calcimycin, calcimycin, 3HA, and benzoate. In this case, enzymatic reactions were terminated by protein precipitation by addition of 100 l of methanol after 2 h. The precipitated protein was removed after centrifugation at 15,000 ϫ g, and the supernatant was removed and analyzed using an Agilent 6530 Series Accurate-Mass Q-TOF LC/MS (Agilent technologies). In the various assays performed, MgCl 2 was sometimes replaced with MnCl 2 , FeCl 2 , or CaCl 2 to assess if these divalent cations could influence the reaction.
Initial reaction velocities of CalC-His proteins with cezomycin, CoA, or ATP were measured in triplicate by substrate concentration variation, one at a time, while keeping that of the other two saturated, which can be determined with several rounds of preliminary testing. The concentrations of CoA, cezomycin, and ATP were varied between 0.01 and 3 mM for determination of their apparent K m values. In a separate series of experiments, it had been deduced that none of the three compounds showed any enzyme inhibition up to that value. A series of 100-l reaction mixtures in microcentrifuge tubes containing 50 mM Tris-HCl (pH 7.5), 200 mM NaCl, 5% glycerol, 2 M CalC, and 1 mM MgCl 2 with or without 1 U inorganic pyrophosphatase were set up, the reactions were initiated by addition of CalC protein, and the mixtures were incubated at 30°C for 4 h, with assays performed starting 5 min after setup and at 15-min intervals. At each assay point, the entire contents of the tube (in triplicate) were assayed for cezomycinCoA by HPLC/MS as described previously (Agilent 6530 series accurate-mass Q-TOF LC/MS). CezomycinCoA synthesized and purified in this project was used for standard curve construction, which was used for comparison with values generated from reaction samples. Prism5 software (Graph-Pad Software, Inc.) was used for the calculation of kinetic parameters.
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